2018 Eosinophilic Esophagitis Drug Development- Pipeline Analysis Report
Eosinophilic Esophagitis (EoE) represents the allergic inflammation of the esophagus that is caused by antigens in both children and adults. It is characterized by esophageal dysfunction and eosinophil infiltration. With increasing incidence and prevalence of the disease, research activities focusing on understanding the disease and development of treatment options are increasing significantly.
Around 15 companies and universities are focusing on developing treatment options for Eosinophilic Esophagitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Eosinophilic Esophagitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Eosinophilic Esophagitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Eosinophilic Esophagitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Around 15 companies and universities are focusing on developing treatment options for Eosinophilic Esophagitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Eosinophilic Esophagitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Eosinophilic Esophagitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Eosinophilic Esophagitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 EOSINOPHILIC ESOPHAGITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Eosinophilic Esophagitis Pipeline Snapshot
2.3 Eosinophilic Esophagitis Pipeline by Phase
2.4 Eosinophilic Esophagitis Pipeline by Company
2.5 Eosinophilic Esophagitis Pipeline by Mechanism of Action
3 EOSINOPHILIC ESOPHAGITIS- COMPANY WISE PIPELINE ANALYSIS
Adare Pharmaceuticals
Biotica Pharmaceuticals
Celgene Corp
DBV Technologies
Dr Falk Pharma
Glycan Biosciences
Quorum Innovations LLC
Sanofi
Shire Plc
4 EOSINOPHILIC ESOPHAGITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN EOSINOPHILIC ESOPHAGITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 EOSINOPHILIC ESOPHAGITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Eosinophilic Esophagitis Pipeline Snapshot
2.3 Eosinophilic Esophagitis Pipeline by Phase
2.4 Eosinophilic Esophagitis Pipeline by Company
2.5 Eosinophilic Esophagitis Pipeline by Mechanism of Action
3 EOSINOPHILIC ESOPHAGITIS- COMPANY WISE PIPELINE ANALYSIS
Adare Pharmaceuticals
Biotica Pharmaceuticals
Celgene Corp
DBV Technologies
Dr Falk Pharma
Glycan Biosciences
Quorum Innovations LLC
Sanofi
Shire Plc
4 EOSINOPHILIC ESOPHAGITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN EOSINOPHILIC ESOPHAGITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018
Figure 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018
Figure 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018
Table 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018
Table 3: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Adare Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
Table 5: Biotica Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
Table 6: Celgene Corp Eosinophilic Esophagitis Pipeline, May 2018
Table 7: DBV Technologies Eosinophilic Esophagitis Pipeline, May 2018
Table 8: Dr Falk Pharma Eosinophilic Esophagitis Pipeline, May 2018
Table 9: Glycan Biosciences Eosinophilic Esophagitis Pipeline, May 2018
Table 10: Quorum Innovations LLC Eosinophilic Esophagitis Pipeline, May 2018
Table 11: Sanofi Eosinophilic Esophagitis Pipeline, May 2018
Table 12: Shire Plc Eosinophilic Esophagitis Pipeline, May 2018
Table 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018
Table 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018
Table 3: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Adare Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
Table 5: Biotica Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
Table 6: Celgene Corp Eosinophilic Esophagitis Pipeline, May 2018
Table 7: DBV Technologies Eosinophilic Esophagitis Pipeline, May 2018
Table 8: Dr Falk Pharma Eosinophilic Esophagitis Pipeline, May 2018
Table 9: Glycan Biosciences Eosinophilic Esophagitis Pipeline, May 2018
Table 10: Quorum Innovations LLC Eosinophilic Esophagitis Pipeline, May 2018
Table 11: Sanofi Eosinophilic Esophagitis Pipeline, May 2018
Table 12: Shire Plc Eosinophilic Esophagitis Pipeline, May 2018
